{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Hemoglobin, increase to grade 3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Hemoglobin, increase to grade 4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Lymphocytes, increase to grade 3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Lymphocytes, increase to grade 4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Neutrophils, increase to grade 3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Neutrophils, increase to grade 4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Platelets, increase to grade 3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Platelets, increase to grade 4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Leukocytes, increase to grade 3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Leukocytes, increase to grade 4"}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"}],"units":"Participants"}],"description":"Blood samples were collected at indicated time points to assess change from baseline in hemoglobin, lymphocytes, neutrophils, platelets, leukocytes. Worst case grade increase from baseline grade was provided for all the hematology tests that were gradable by National Cancer Institute Common Terminology Criteria (NCI CTCAE, Version 5.0, 2017). Grade 1 = Mild AE; Grade 2 = Moderate AE; Grade 3 = Severe AE; Grade 4 = Life-threatening or disabling AE. Data for any participants with worst-case grade changes (Increase to Grade 3 or Increase to Grade 4) post-baseline were presented. Baseline was defined as latest pre-dose assessment (day 1) with a non-missing value, including those from unscheduled visits.","groups":[{"description":"Participants with relapsed/refractory multiple myeloma (RRMM) were administered with 2.5 milligram per kilogram (mg/kg) belantamab mafodotin intravenous (IV) infusion over 30-60 minutes on day 1 of each 21-days cycle. Participants were treated until disease progression, intolerable toxicity, end of study or informed consent withdrawal.","id":"OG000","title":"Belantamab Mafodotin"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All treated population","reportingStatus":"POSTED","timeFrame":"Baseline (day 1) and up to 21 months","title":"Number of Participants With Worst- Case Grade Changes Post-baseline in Hematology Parameter: Hemoglobin, Lymphocytes, Neutrophils, Platelets, Leukocytes","type":"SECONDARY","unitOfMeasure":"Participants"}